The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Interleukin-8 in cancer pathogenesis, treatment and follow-up
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Novel cell death program leads to neutrophil extracellular traps
Fuchs, T. A., Abed, U., Goosmann, C., Hurwitz, R., Schulze, I., Wahn, V., Weinrauch, Y., Brinkmann, V., & Zychlinsky, A. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200606027 · Cited by 3,197
Cancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343
Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease
Turner, M. D., Nedjai, B., Hurst, T., & Pennington, D. J. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.05.014 · Cited by 2,162
The Interleukin-8 Pathway in Cancer
Waugh, D. J. J., & Wilson, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4843 · Cited by 2,103
Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity
Griffith, J. W., Sokol, C. L., & Luster, A. D. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120145 · Cited by 2,059
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
The Cancer Stem Cell Niche: How Essential Is the Niche in Regulating Stemness of Tumor Cells?
Plaks, V., Kong, N., & Werb, Z. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.02.015 · Cited by 1,557
Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis
Cools-Lartigue, J., Spicer, J., McDonald, B., Gowing, S., Chow, S., Giannias, B., Bourdeau, F., Kubes, P., & Ferri, L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67484 · Cited by 1,395
Li, A., Dubey, S., Varney, M. L., Dave, B. J., & Singh, R. K. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.3369 · Cited by 1,332
Decisions About Dendritic Cells: Past, Present, and Future
Steinman, R. M. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-100311-102839 · Cited by 1,274
History of myeloid-derived suppressor cells
Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148
A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P. G., Manova-Todorova, K., Leversha, M., Hogg, N., Seshan, V. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.042 · Cited by 1,085
Steele, C. W., Karim, S. A., Leach, J. D. G., Bailey, P., Upstill-Goddard, R., Rishi, L., Foth, M., Bryson, S., McDaid, K., Wilson, Z., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.014 · Cited by 845
Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases
Ha, H., Debnath, B., & Neamati, N. (2017) · Theranostics · doi:10.7150/thno.15625 · Cited by 789
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Highfill, S. L., Cui, Y., Giles, A. J., Smith, J. P., Zhang, H., Morse, E., Kaplan, R. N., & Mackall, C. L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007974 · Cited by 767
CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts
Ginestier, C., Liu, S., Diebel, M. E., Korkaya, H., Luo, M., Brown, M., Wicinski, J., Cabaud, O., Charafe-Jauffret, E., Birnbaum, D., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39397 · Cited by 747
Metastatic Stem Cells: Sources, Niches, and Vital Pathways
Oskarsson, T., Batlle, E., & Massagué, J. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.02.002 · Cited by 708
Tohme, S., Yazdani, H. O., Al-Khafaji, A. B., Chidi, A. P., Loughran, P., Mowen, K., Wang, Y., Simmons, R. L., Huang, H., & Tsung, A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1591 · Cited by 694
The CXCL8-CXCR1/2 pathways in cancer
Liu, Q., Li, A., Tian, Y., Wu, J. D., Liu, Y., Li, T., Chen, Y., Han, X., & Wu, K. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.08.002 · Cited by 662
The role of CXC chemokines and their receptors in cancer
Vandercappellen, J., Van Damme, J., & Struyf, S. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.050 · Cited by 643
Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer
Spira, A., Beane, J. E., Shah, V., Steiling, K., Liu, G., Schembri, F., Gilman, S., Dumas, Y.-M., Calner, P., Sebastiani, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1556 · Cited by 572
Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8
Sekido, N., Mukaida, N., Harada, A., Nakanishi, I., Watanabe, Y., & Matsushima, K. (1993) · Nature · doi:10.1038/365654a0 · Cited by 514
Chow, M. T., & Luster, A. D. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0160 · Cited by 485
Sanmamed, M. F., Perez-Gracia, J. L., Schalper, K. A., Fusco, J. P., Gonzalez, A., Rodriguez-Ruiz, M. E., Oñate, C., Perez, G., Alfaro, C., Martín-Algarra, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx190 · Cited by 458
Self-citationThe Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
Umansky, V., Blattner, C., Gebhardt, C., & Utikal, J. (2016) · Vaccines · doi:10.3390/vaccines4040036 · Cited by 438
Delayed Wound Healing in CXCR2 Knockout Mice
Devalaraja, R. M., Nanney, L. B., Qian, Q., Du, J., Yu, Y., Devalaraja, M. N., & Richmond, A. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00034.x · Cited by 429
Neutrophils in Cancer: Two Sides of the Same Coin
Uribe-Querol, E., & Rosales, C. (2015) · Journal of Immunology Research · doi:10.1155/2015/983698 · Cited by 422
Alfaro, C., Teijeira, A., Oñate, C., Pérez, G., Sanmamed, M. F., Andueza, M. P., Alignani, D., Labiano, S., Azpilikueta, A., Rodriguez-Paulete, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2463 · Cited by 417
Self-citationInterleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
Huang, D., Ding, Y., Zhou, M., Rini, B. I., Petillo, D., Qian, C.-N., Kahnoski, R., Futreal, P. A., Furge, K. A., & Teh, B. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3965 · Cited by 417
Dendritic cells: Understanding immunogenicity
Steinman, R. M. (2007) · European Journal of Immunology · doi:10.1002/eji.200737400 · Cited by 401
Interleukin-8 and the chemokine family
Baggiolini, M., Loetscher, P., & Moser, B. (1995) · International Journal of Immunopharmacology · doi:10.1016/0192-0561(94)00088-6 · Cited by 400
The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance
David, J., Dominguez, C., Hamilton, D., & Palena, C. (2016) · Vaccines · doi:10.3390/vaccines4030022 · Cited by 395
Myeloid Lineage Commitment from the Hematopoietic Stem Cell
Iwasaki, H., & Akashi, K. (2007) · Immunity · doi:10.1016/j.immuni.2007.06.004 · Cited by 394
Martin, D., Galisteo, R., & Gutkind, J. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.c800207200 · Cited by 388
IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors
Hammond, M. E., Lapointe, G. R., Feucht, P. H., Hilt, S., Gallegos, C. A., Gordon, C. A., Giedlin, M. A., Mullenbach, G., & Tekamp-Olson, P. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1428 · Cited by 367
Huang, S., Mills, L., Mian, B., Tellez, C., McCarty, M., Yang, X.-D., Gudas, J. M., & Bar-Eli, M. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64164-8 · Cited by 361
The chemotaxis of M1 and M2 macrophages is regulated by different chemokines
Xuan, W., Qu, Q., Zheng, B., Xiong, S., & Fan, G.-H. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.1a0314-170r · Cited by 357
Chemokines in tumor progression and metastasis
Sarvaiya, P. J., Guo, D., Ulasov, I., Gabikian, P., & Lesniak, M. S. (2013) · Oncotarget · doi:10.18632/oncotarget.1426 · Cited by 348
Bertini, R., Allegretti, M., Bizzarri, C., Moriconi, A., Locati, M., Zampella, G., Cervellera, M. N., Di Cioccio, V., Cesta, M. C., Galliera, E., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402090101 · Cited by 333
Chen, J. J. W., Yao, P., Yuan, A., Hong, T.-M., Shun, C., Kuo, M., Lee, Y.-C., & Yang, P. (2003) · PubMed · Cited by 308
Depletion of CXCR2 Inhibits Tumor Growth and Angiogenesis in a Murine Model of Lung Cancer
Keane, M. P., Belperio, J. A., Xue, Y. Y., Burdick, M. D., & Strieter, R. M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2853 · Cited by 305
Lee, Y. S., Choi, I., Ning, Y., Kim, N. Y., Khatchadourian, V, Yang, D., Chung, H. K., Choi, D., LaBonte, M. J., Ladner, R. D., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.177 · Cited by 292
Li, A., Varney, M. L., Valasek, J., Godfrey, M., Dave, B. J., & Singh, R. K. (2005) · Angiogenesis · doi:10.1007/s10456-005-5208-4 · Cited by 285
Matsuo, Y., Ochi, N., Sawai, H., Yasuda, A., Takahashi, H., Funahashi, H., Takeyama, H., Tong, Z., & Guha, S. (2009) · International Journal of Cancer · doi:10.1002/ijc.24040 · Cited by 279
The functional significance behind expressing two IL–8 receptor types on PMN
Stillie, R., Farooq, S. M., Gordon, J. R., & Stadnyk, A. W. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0208125 · Cited by 272
Sanmamed, M. F., Carranza-Rua, O., Alfaro, C., Oñate, C., Martín-Algarra, S., Perez, G., Landazuri, S. F., Gonzalez, Á., Gross, S., Rodriguez, I., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3203 · Cited by 256
Self-citationRecent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells
Singh, J. K., Simões, B. M., Howell, S. J., Farnie, G., & Clarke, R. B. (2013) · Breast Cancer Research · doi:10.1186/bcr3436 · Cited by 249
Interleukin-8/CXCL8 is a growth factor for human lung cancer cells
Zhu, Y. M., Webster, S. J., Flower, D., & Woll, P. J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602227 · Cited by 241
Schott, A. F., Goldstein, L. J., Cristofanilli, M., Ruffini, P. A., McCanna, S., Reuben, J. M., Perez, R. P., Kato, G., & Wicha, M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2748 · Cited by 238
Neutrophil receptors for interleukin-8 and related CXC chemokines.
Murphy, P. M. (1997) · PubMed · Cited by 228
Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies
Scappaticci, F. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.033 · Cited by 225
CXCR2 antagonists for the treatment of pulmonary disease
Chapman, R. W., Phillips, J. E., Hipkin, R. W., Curran, A. K., Lundell, D., & Fine, J. S. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.10.005 · Cited by 214
Asfaha, S., Dubeykovskiy, A. N., Tomita, H., Yang, X., Stokes, S., Shibata, W., Friedman, R. A., Ariyama, H., Dubeykovskaya, Z. A., Muthupalani, S., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.09.057 · Cited by 209
Bizzarri, C., Beccari, A. R., Bertini, R., Cavicchia, M. R., Giorgini, S., & Allegretti, M. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.04.002 · Cited by 205
Murine CXCR1 Is a Functional Receptor for GCP-2/CXCL6 and Interleukin-8/CXCL8
Fan, X., Patera, A. C., Pong-Kennedy, A., Deno, G., Gonsiorek, W., Manfra, D. J., Vassileva, G., Zeng, M., Jackson, C., Sullivan, L., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607705200 · Cited by 204
Immunomodulatory Activity of VEGF in Cancer
(2017) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2016.09.007 · Cited by 194
Interleukin-8 in Breast Cancer Progression
Todorović-Raković, N., & Milovanović, J. (2013) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2013.0023 · Cited by 186
Stadtmann, A., & Zarbock, A. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00263 · Cited by 182
Schultheis, A. M., Lurje, G., Rhodes, K. E., Zhang, W., Yang, D., Garcia, A. A., Morgan, R., Gandara, D., Scudder, S., Oza, A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0351 · Cited by 182
IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells
Schinke, C., Giricz, O., Li, W., Shastri, A., Gordon, S., Barreyro, L., Bhagat, T., Bhattacharyya, S., Ramachandra, N., Bartenstein, M., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621631 · Cited by 180
Mazzolini, G., Alfaro, C., Sangro, B., Feijoó, E., Ruiz, J., Benito, A., Tirapu, I., Arina, A., Sola, J., Herraiz, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.463 · Cited by 179
Self-citationSkov, L., Beurskens, F. J., Zachariae, C. O. C., Reitamo, S., Teeling, J., Satijn, D., Knudsen, K. M., Boot, E. P. J., Hudson, D., Baadsgaard, O., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.669 · Cited by 177
The Role of the Vascular Phase in Solid Tumor Growth: A Historical Review
Ribatti, D., Vacca, A., & Dammacco, F. (1999) · Neoplasia · doi:10.1038/sj.neo.7900038 · Cited by 173
Singer, M., & Sansonetti, P. J. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.4197 · Cited by 172
Singh, S., Sadanandam, A., Nannuru, K. C., Varney, M. L., Mayer‐Ezell, R., Bond, R. W., & Singh, R. K. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2387 · Cited by 160
Podolin, P. L., Bolognese, B. J., Foley, J. J., Schmidt, D. B., Buckley, P. T., Widdowson, K. L., Jin, Q., White, J. R., Lee, J. M., Goodman, R. B., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.11.6435 · Cited by 159
Matsumoto, T., Ikeda, K., Mukaida, N., Harada, A., Matsumoto, Y., Yamashita, J., & Matsushima, K. (1997) · PubMed · Cited by 154
Raghuwanshi, S. K., Su, Y., Singh, V., Haynes, K., Richmond, A. J., & Richardson, R. M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201114 · Cited by 150
Mian, B. M., Dinney, C. P., Bermejo, C. E., Sweeney, P., Tellez, C. S., Yang, X., Gudas, J. M., McConkey, D. J., & Bar‐Eli, M. (2003) · PubMed · Cited by 148
Rationale and Means to Target Pro-Inflammatory Interleukin-8 (CXCL8) Signaling in Cancer
Campbell, L. M., Maxwell, P. J., & Waugh, D. J. J. (2013) · Pharmaceuticals · doi:10.3390/ph6080929 · Cited by 147
Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment
Атретханы, К.-С. Н., Drutskaya, M. S., Nedospasov, S. A., Grivennikov, S. I., & Kuprash, D. V. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.011 · Cited by 131
Mukaida, N., Sasaki, S., & Baba, T. (2014) · Mediators of Inflammation · doi:10.1155/2014/170381 · Cited by 128
Interleukin-8, a promising predictor for prognosis of pancreatic cancer
Chen, Y. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i10.1123 · Cited by 124
Dendritic cells delivered inside human carcinomas are sequestered by interleukin‐8
Feijoó, E., Alfaro, C., Mazzolini, G. D., Serra, P., Peñuelas, I., Arina, A., Huarte, E., Tirapu, I., Palencia, B., Murillo, O., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21046 · Cited by 122
Self-citationSharma, B., Nawandar, D. M., Nannuru, K. C., Varney, M. L., & Singh, R. K. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0529 · Cited by 116
Larsen, C. G., Thomsen, M. K., Gesser, B., Thomsen, P., Deleuran, B. W., Nowak, J., Skødt, V., Thomsen, H. K., Deleuran, M. S., & Thestrup‐Pedersen, K. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.4.2151 · Cited by 115
Petzelbauer, P., Watson, C. A., Watson, C. A., Pfau, S. E., & Pober, J. S. (1995) · Cytokine · doi:10.1006/cyto.1995.0031 · Cited by 110
Nilsson, G. P., Mikovits, J. A., Metcalfe, D. D., et al. (1999) · Blood · doi:10.1182/blood.v93.9.2791 · Cited by 104
CXCL8 and Its Cognate Receptors in Melanoma Progression and Metastasis
Singh, S., Singh, A. P., Sharma, B., Owen, L. B., & Singh, R. K. (2009) · Future Oncology · doi:10.2217/fon.09.128 · Cited by 104
Marriott, H. M., Gascoyne, K. A., Gowda, R., Geary, I., Nicklin, M. J. H., Iannelli, F., Pozzi, G., Mitchell, T. J., Whyte, M. K. B., Sabroe, I., et al. (2011) · Infection and Immunity · doi:10.1128/iai.05697-11 · Cited by 102
Cytokine Regulation of Metastasis and Tumorigenicity
Yao, M., Brummer, G., Acevedo, D. S., & Cheng, N. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.05.005 · Cited by 102
The Chemokine CXCL8 in Carcinogenesis and Drug Response
Gales, D. N., Clark, C. E., Manne, U., & Samuel, T. (2013) · ISRN Oncology · doi:10.1155/2013/859154 · Cited by 99
Tumor angiogenesis and therapy
Cao, Y. (2005) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(05)80070-8 · Cited by 98
Chemokine Receptor Signaling and the Hallmarks of Cancer
Lacalle, R. A., Blanco, R., Carmona‐Rodríguez, L., Martín‐Leal, A., Mira, E., & Mañes, S. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.09.011 · Cited by 98
Myeloid‐Derived Suppressor Cells and Therapeutic Strategies in Cancer
Katoh, H., & Watanabe, M. (2015) · Mediators of Inflammation · doi:10.1155/2015/159269 · Cited by 91
CXCR1/2 Inhibition Blocks and Reverses Type 1 Diabetes in Mice
Citro, A., Valle, A., Cantarelli, E., Mercalli, A., Pellegrini, S., Liberati, D., Daffonchio, L., Kastsiuchenka, O., Ruffini, P. A., Battaglia, M., et al. (2014) · Diabetes · doi:10.2337/db14-0443 · Cited by 90
Chi, N., Tan, Z., Ma, K., Bao, L., & Yun, Z. (2014) · PubMed · Cited by 88
Manfroi, B., McKee, T., Mayol, J. F., Tabruyn, S. P., Moret, S., VILLIERS, C. L., Righini, C. A., Dyer, M. J. S., Callanan, M. B., Schneider, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0786 · Cited by 85
Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling
Brandolini, L., Cristiano, L., Fidoamore, A., Pizzol, M. D., Giacomo, E. D., Florio, T. M., Confalone, G., Galante, A., Cinque, B., Benedetti, E., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6234 · Cited by 83
Singh, S., Wu, S., Varney, M. L., Singh, A. P., & Singh, R. K. (2011) · Microvascular Research · doi:10.1016/j.mvr.2011.06.011 · Cited by 83
Neutrophils recruited by CXCR1/2 signalling mediate post‐incisional pain
Carreira, E. U., Carregaro, V., Teixeira, M. M., Moriconi, A., Aramini, A., Verri, W. A., Jr., Ferreira, S. H., Cunha, F. Q., & Cunha, T. M. (2012) · European Journal of Pain · doi:10.1002/j.1532-2149.2012.00240.x · Cited by 82
Mini-review series: focus on chemokines
Comerford, I., & McColl, S. R. (2011) · Immunology & Cell Biology · doi:10.1038/icb.2010.164 · Cited by 81
Passaro, C., Borriello, F., Vastolo, V., Somma, S. D., Scamardella, E., Gigantino, V., Franco, R., Marone, G., & Portella, G. (2015) · Oncotarget · doi:10.18632/oncotarget.6430 · Cited by 69
Role of chemokine receptor CXCR2 expression in mammary tumor growth, angiogenesis and metastasis
Singh, R., Nannuru, K. C., Sharma, B., & Varney, M. L. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.92308 · Cited by 67
Hampering Immune Suppressors: Therapeutic Targeting of Myeloid-Derived Suppressor Cells in Cancer
Albeituni, S., Ding, C., & Yan, J. (2013) · The Cancer Journal · doi:10.1097/ppo.0000000000000006 · Cited by 65
Busch‐Petersen, J. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266106061345 · Cited by 60
Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma
Sharma, B., Singh, S., Varney, M. L., & Singh, R. K. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728221003652471 · Cited by 56
Circulating myeloid-derived suppressor cells in patients with pancreatic cancer
Xu, X., Hu, J., Wang, M., Peng, F., Tian, R., Guo, X., Xie, Y., & Qin, R. (2016) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(15)60413-1 · Cited by 50
Clinical implications of antigen transfer mechanisms from malignant to dendritic cells
Arina, A., Tirapu, I., Alfaro, C., Rodríguez-Calvillo, M., Mazzolini, G. D., Inogés, S., López, A., Feijoó, E., Bendandi, M., & Melero, I. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(02)00956-6 · Cited by 49
Self-citationAlfaro, C., Suárez, N., Martínez‐Forero, I., Palazón, A., Rouzaut, A., Solano, S., Feijoó, E., Gúrpide, A., Bolaños, E., Erro, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017922 · Cited by 46
Self-citationRole of IL-8 induced angiogenesis in uveal melanoma
Lattanzio, L., Tonissi, F., Torta, I., Gianello, L., Russi, E. G., Milano, G. A., Merlano, M. C., & Nigro, C. L. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0005-1 · Cited by 44
Chemokines and their receptors: insights from molecular modeling and crystallography
Kufareva, I. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.07.006 · Cited by 40
Kemp, D. M., Pidich, A., Larijani, M., Jonas, R. A., Lash, E., Sato, T., Terai, M., Pizzol, M. D., Allegretti, M., Igoucheva, O., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14803 · Cited by 40
Dendritic Cells Take up and Present Antigens from Viable and Apoptotic Polymorphonuclear Leukocytes
Alfaro, C., Suárez, N., Oñate, C., Perez‐Gracia, J. L., Martínez‐Forero, I., Hervás‐Stubbs, S., Rodríguez, I., Pérez, G., Bolaños, E., Palazón, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029300 · Cited by 35
Self-citationChoi, S. H., Kwon, O., Park, J. Y., Kim, D. Y., Ahn, S. H., Kim, S. U., Ro, S. W., Kim, K. S., Park, J. H., Kim, S., et al. (2013) · Liver International · doi:10.1111/liv.12375 · Cited by 35
Gyanchandani, R., Sano, D., Alves, M. V. O., Klein, J. D., Knapick, B. A., Oh, S., Myers, J. N., & Kim, S. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.03.452 · Cited by 31
Zhu, K., Shen, Q., Ulrich, M., & Zheng, M. (2000) · PubMed · Cited by 31
Tan, P. H. S., Chia, S. S., Toh, S. L., Goh, J. C., & Nathan, S. S. (2013) · Tissue Engineering Part A · doi:10.1089/ten.tea.2013.0245 · Cited by 28
Immunogenic Cell Death and Cross-Priming Are Reaching the Clinical Immunotherapy Arena
Melero, I., Arina, A., Murillo, O., Dubrot, J., Alfaro, C., Perez‐Gracia, J. L., Bendandi, M., & Hervás‐Stubbs, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0314 · Cited by 26
Self-citationArina, A., Murillo, O., Hervás‐Stubbs, S., Azpilikueta, A., Dubrot, J., Tirapu, I., Huarte, E., Alfaro, C., Perez‐Gracia, J. L., González‐Aseguinolaza, G., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22795 · Cited by 17
Self-citation
Cited by
Cytokines in clinical cancer immunotherapy
Berraondo, P., Sanmamed, M. F., Ochoa, M. C., Etxeberria, I., Aznar, M. A., Pérez-Gracia, J. L., Rodríguez-Ruiz, M. E., Ponz-Sarvise, M., Castañón, E., & Melero, I. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0328-y · Cited by 1,205
Self-citationHarnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
Li, K., Shi, H., Zhang, B., Ou, X., Ma, Q., Chen, Y., Shu, P., Li, D., & Wang, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00670-9 · Cited by 988
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Tie, Y., Tang, F., Wei, Y.-Q., & Wei, X.-W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01282-8 · Cited by 591
Cambier, S., Gouwy, M., & Proost, P. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-00974-6 · Cited by 591
Metadata
- Authors
- Alfaro, C., Sanmamed, M. F., Rodríguez-Ruiz, M. E., Teijeira, Á., Oñate, C., González, Á., Ponz, M., Schalper, K. A., Pérez-Gracia, J. L., & Melero, I.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 60
- Pages
- 24-31
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2751633859
- Cited by
- 372
- References
- 111
- FWCI
- 11.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.